Right, let’s dive into Eco Animal Health’s latest full-year results. The headline? A tidy profit jump and a significant vaccine milestone, all while North America’s pulling its weight. For investors tracking this AIM-listed animal health player, there’s substance beneath the surface.
Financials: Margins Flex, Profits Pop
First, the numbers. Group revenue landed at £79.6 million, down from £89.4 million last year. But hold the frown – this was expected, flagged in earlier updates, and crucially, it came with a strong second-half recovery. The real story is in the quality of earnings:
- Profit Before Tax Up 33%: Jumped to £4.0 million (2024: £3.0 million).
- EPS Surge: Earnings per share rocketed 61% to 2.49p (2024: 1.55p).
- Gross Margin Expansion: Hit 45% (up from 42%), driven by disciplined pricing, cost control, and a favourable sales mix (hello, North America!). On constant currency, it was even healthier at 46.2%.
- Adjusted EBITDA: £7.3 million (slightly down from £8.0m), but importantly in-line with revised expectations and with an improved margin of 9.2%.
- Cash is King: Net cash strengthened to £25.0 million (up from £22.4m), with a healthy 40% held outside China. A £15m credit facility sits undrawn.
So, while top-line took a dip, the focus on margin discipline and operational efficiency delivered a much healthier bottom line. That EPS growth is particularly eye-catching.
Operational Wins: Aivlosin Anchors, Vaccines Advance
Flagship antimicrobial Aivlosin® remains the workhorse (£72.9m sales), showing robust demand, especially in its core markets. But the standout operational news is the R&D pipeline hitting a crucial inflection point:
- Vaccine Milestone Achieved: The regulatory dossier for ECOVaxxin® MS (a poultry vaccine targeting Mycoplasma synoviae) was submitted to the European Medicines Agency (EMA).
- More to Come: Further submissions, including for its sister vaccine ECOVaxxin® MG (Mycoplasma gallisepticum), are expected within the next 12 months. Commercial launches are targeted from 2026.
- Pipeline Promise: The company highlighted progress across its R&D slate, forecasting up to 9 product approvals in the US and EU over the next 5-6 years.
This marks a significant shift. While Aivlosin drives today’s cash flow, these vaccines represent the tangible beginning of the next growth phase, potentially reducing reliance on the antimicrobial segment long-term.
Regional Mix: North America Shines
Geography mattered this year. The star performer was unequivocally North America:
- Revenue Growth: +16% at actual rates (£21.4m), +18% at constant currency (£21.9m).
- Driven by Disease: Demand was fuelled by outbreaks of Porcine Reproductive and Respiratory Syndrome Virus (PRRSv) and enteric diseases requiring Aivlosin®.
Elsewhere, it was mixed:
- China/Japan: Challenging start but recovered strongly in H2 (H2 constant currency sales +3% YoY), with post-year-end performance noted as budget-beating.
- South & Southeast Asia: Down significantly (-30% constant currency) primarily due to losing a major Thai customer, though nascent markets like Bangladesh and the Philippines showed promise.
- Latin America: Brazil stable, Mexico struggled with channel stock and generic pressure, Colombia faced distribution changes (now resolved), Argentina grew strongly.
- Europe: Steady, with Spain resuming sales of a key Aivlosin® formulation.
Strategic Moves: Sharpening Focus & Rewarding Talent
Management hasn’t been idle:
- Non-Core Disposals: Sold Ecomectin® Horsepaste (€1.3m) and parasite licences in Southern Africa (£0.5m), freeing up resources for core priorities (pigs, poultry, vaccines).
- R&D Investment: Spend increased to £8.6m (planned), with over half (53%) now focused on late-stage assets like the mycoplasma vaccines.
- Share Buy-Back Launched: Post-year-end, initiated to support future employee share incentive vesting – a sensible use of the strong cash position to retain key talent.
Governance & Outlook: Pipeline in the Headlights
The baton passed in the boardroom with Dr. Joachim Hasenmaier succeeding Dr. Andrew Jones as Chairman. The dividend remains paused (reinvestment priority), which makes sense given the pipeline’s potential.
CEO David Hallas struck a confident but pragmatic note. While acknowledging challenges like currency swings and lower disease incidence in some regions, he emphasised:
- Continued Aivlosin® Strength: Particularly in high-growth territories like North America and LatAm.
- China Recovery: Encouraging signs.
- R&D Execution is Key: The focus is squarely on advancing the vaccine pipeline towards those 2026+ launches. The R&D Day in March underscored this commitment.
They also noted vigilance on tariffs but highlighted mitigating actions taken in North America post-year-end.
The Bottom Line: Steady Ship, Voyage Set
Eco Animal Health delivered a year of solid underlying progress. Yes, revenue dipped, but profitability and cash generation improved markedly. The standout developments are the tangible advancement of the vaccine pipeline (that EMA submission is a big deal) and the exceptional performance in North America. The company is managing costs well, disposing of non-core bits, and sitting on a robust cash pile.
The investment case now hinges more than ever on the successful commercialisation of that R&D pipeline starting next year. If they can translate these regulatory submissions into marketable products, the current profit surge could be the precursor to a significant new growth chapter. For now, it’s a case of steady as she goes, with the horizon looking increasingly interesting.
